Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Groups, To Evaluate And Compare The Safety, Tolerability And Efficacy Of Two Dosages Of Inhaled TPI ASM8 Administered For 14 Days In Patients With Mild to Moderate Asthma.
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2012
At a glance
- Drugs ASM 8 (Primary)
- Indications Asthma
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 14 Dec 2008 Planned end date changed from 1 Jun 2008 to 1 Dec 2007 as reported by ClinicalTrials.gov.
- 30 Jun 2008 Status changed from recruiting to discontinued, reported by ClinicalTrials.gov.